DE69126643T2 - Methode und Vorrichtung zur Entfernung von Heparin - Google Patents
Methode und Vorrichtung zur Entfernung von HeparinInfo
- Publication number
- DE69126643T2 DE69126643T2 DE69126643T DE69126643T DE69126643T2 DE 69126643 T2 DE69126643 T2 DE 69126643T2 DE 69126643 T DE69126643 T DE 69126643T DE 69126643 T DE69126643 T DE 69126643T DE 69126643 T2 DE69126643 T2 DE 69126643T2
- Authority
- DE
- Germany
- Prior art keywords
- blood
- porous medium
- heparin
- plasma
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 62
- 229920000669 heparin Polymers 0.000 title claims description 62
- 229960002897 heparin Drugs 0.000 title claims description 62
- 238000000034 method Methods 0.000 title claims description 35
- 239000000178 monomer Substances 0.000 claims description 59
- 239000000758 substrate Substances 0.000 claims description 55
- 210000004369 blood Anatomy 0.000 claims description 53
- 239000008280 blood Substances 0.000 claims description 53
- 239000000835 fiber Substances 0.000 claims description 41
- 239000011159 matrix material Substances 0.000 claims description 26
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 15
- XFCMNSHQOZQILR-UHFFFAOYSA-N 2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOC(=O)C(C)=C XFCMNSHQOZQILR-UHFFFAOYSA-N 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 230000015271 coagulation Effects 0.000 claims description 12
- 238000005345 coagulation Methods 0.000 claims description 12
- 239000003114 blood coagulation factor Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 229920001707 polybutylene terephthalate Polymers 0.000 claims description 8
- -1 polybutylene terephthalate Polymers 0.000 claims description 7
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 229940019700 blood coagulation factors Drugs 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920000098 polyolefin Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000010979 pH adjustment Methods 0.000 claims 3
- 239000000243 solution Substances 0.000 description 30
- 210000002381 plasma Anatomy 0.000 description 29
- 239000000523 sample Substances 0.000 description 29
- 239000007788 liquid Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 16
- 125000001453 quaternary ammonium group Chemical group 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 102000007327 Protamines Human genes 0.000 description 11
- 108010007568 Protamines Proteins 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 229940048914 protamine Drugs 0.000 description 10
- 239000003463 adsorbent Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 239000002250 absorbent Substances 0.000 description 7
- 230000002745 absorbent Effects 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 239000012503 blood component Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- FBCQUCJYYPMKRO-UHFFFAOYSA-N prop-2-enyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC=C FBCQUCJYYPMKRO-UHFFFAOYSA-N 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 4
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000001302 tertiary amino group Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 241000393496 Electra Species 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000034964 establishment of cell polarity Effects 0.000 description 2
- CFUNGMSJDZBIDN-UHFFFAOYSA-N ethyl prop-2-enoate;trimethylazanium;chloride Chemical compound [Cl-].C[NH+](C)C.CCOC(=O)C=C CFUNGMSJDZBIDN-UHFFFAOYSA-N 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010559 graft polymerization reaction Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 239000003658 microfiber Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UZNHKBFIBYXPDV-UHFFFAOYSA-N trimethyl-[3-(2-methylprop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].CC(=C)C(=O)NCCC[N+](C)(C)C UZNHKBFIBYXPDV-UHFFFAOYSA-N 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- UABZBFJRDPRXJR-UHFFFAOYSA-N 2-methylidenebutanoate;trimethylazanium Chemical compound C[NH+](C)C.CCC(=C)C([O-])=O UABZBFJRDPRXJR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 206010029538 Non-cardiogenic pulmonary oedema Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- HVVWZTWDBSEWIH-UHFFFAOYSA-N [2-(hydroxymethyl)-3-prop-2-enoyloxy-2-(prop-2-enoyloxymethyl)propyl] prop-2-enoate Chemical compound C=CC(=O)OCC(CO)(COC(=O)C=C)COC(=O)C=C HVVWZTWDBSEWIH-UHFFFAOYSA-N 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000013132 cardiothoracic surgery Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- SDYRIBONPHEWCT-UHFFFAOYSA-N n,n-dimethyl-2-phenylethenamine Chemical compound CN(C)C=CC1=CC=CC=C1 SDYRIBONPHEWCT-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- GRPURDFRFHUDSP-UHFFFAOYSA-N tris(prop-2-enyl) benzene-1,2,4-tricarboxylate Chemical compound C=CCOC(=O)C1=CC=C(C(=O)OCC=C)C(C(=O)OCC=C)=C1 GRPURDFRFHUDSP-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3675—Deactivation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/04—Processes using organic exchangers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/08—Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/12—Macromolecular compounds
- B01J41/14—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J47/00—Ion-exchange processes in general; Apparatus therefor
- B01J47/018—Granulation; Incorporation of ion-exchangers in a matrix; Mixing with inert materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- Y10T436/255—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] including use of a solid sorbent, semipermeable membrane, or liquid extraction
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Sustainable Development (AREA)
- External Artificial Organs (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/552,138 US5151192A (en) | 1990-07-13 | 1990-07-13 | Method for removing heparin from blood or plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69126643D1 DE69126643D1 (de) | 1997-07-31 |
| DE69126643T2 true DE69126643T2 (de) | 1997-10-23 |
Family
ID=24204076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69126643T Expired - Fee Related DE69126643T2 (de) | 1990-07-13 | 1991-07-12 | Methode und Vorrichtung zur Entfernung von Heparin |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5151192A (enExample) |
| EP (1) | EP0466178B1 (enExample) |
| JP (1) | JP2679894B2 (enExample) |
| KR (1) | KR920002635A (enExample) |
| AU (1) | AU653731B2 (enExample) |
| CA (1) | CA2046807A1 (enExample) |
| DE (1) | DE69126643T2 (enExample) |
| GB (1) | GB2245844B (enExample) |
| IL (1) | IL98799A0 (enExample) |
| TW (1) | TW207958B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270004A (en) | 1989-10-01 | 1993-12-14 | Minntech Corporation | Cylindrical blood heater/oxygenator |
| US5362406A (en) * | 1990-07-27 | 1994-11-08 | Pall Corporation | Leucocyte depleting filter device and method of use |
| US5354472A (en) * | 1991-12-04 | 1994-10-11 | Cobe Cardiovascular, Inc. | Anion exchange materials comprised of derivatized cellulose-polyester composites |
| US5648070A (en) * | 1991-12-04 | 1997-07-15 | Cobe Laboratories, Inc. | Biocompatible anion exchange materials |
| US5416198A (en) * | 1993-02-05 | 1995-05-16 | Research Medical, Inc. | Selective sorbent removal system using polycation activated substrates |
| ES2119201T3 (es) * | 1993-04-28 | 1998-10-01 | Focal Inc | Aparato, producto y uso relacionados con la fototermoconformacion intraluminal. |
| DE4429660B4 (de) * | 1994-08-20 | 2004-02-12 | Dade Behring Marburg Gmbh | Zusatzmittel für diagnostische Tests zur Bestimmung der Gerinnungsfähigkeit des Blutes, Verfahren zur Reduzierung der Beeinflussung von diagnostischen Tests durch Heparin und Verwendung von Metallsalzen zu diesen Zwecken |
| US5630946A (en) * | 1995-02-15 | 1997-05-20 | Pall Corporation | Method for processing a biological fluid including leukocyte removal in an extracorporeal circuit |
| US5628727A (en) * | 1995-08-15 | 1997-05-13 | Hakky; Said I. | Extracorporeal virioncidal apparatus |
| US5787901A (en) * | 1997-01-28 | 1998-08-04 | Akzo Nobel N.V. | Method for the measurement of blood coagulation properties with absorbent materials |
| US6197289B1 (en) | 1997-07-01 | 2001-03-06 | Terumo Cardiovascular Systems Corporation | Removal of biologically active agents |
| US6146771A (en) * | 1997-07-01 | 2000-11-14 | Terumo Cardiovascular Systems Corporation | Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine |
| CA2301174C (en) * | 1997-08-16 | 2007-11-27 | Orthogen Gentechnologie Gmbh | A method for inducing therapeutically-effective proteins |
| US6159232A (en) | 1997-12-16 | 2000-12-12 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
| US6478808B2 (en) | 1997-12-17 | 2002-11-12 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
| US6114466A (en) * | 1998-02-06 | 2000-09-05 | Renal Tech International Llc | Material for purification of physiological liquids of organism |
| US6193681B1 (en) * | 1998-09-14 | 2001-02-27 | American Immuno Tech, Llc. | Septicemia prevention and treatment system |
| IT1304828B1 (it) * | 1998-11-12 | 2001-04-05 | Braun Carex Spa | Filtro adsorbitore di eparina e/o endotossine nel plasma e/o nelsangue. |
| US20030069601A1 (en) * | 1998-12-15 | 2003-04-10 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
| EP1180977B1 (en) | 1999-06-01 | 2011-12-28 | Closys Corporation | Clotting cascade initiating apparatus and methods of use |
| JP4289886B2 (ja) * | 2001-05-09 | 2009-07-01 | バイオインターラクションズ リミテッド | 創傷閉鎖システム及び方法 |
| JP2002369881A (ja) * | 2001-06-14 | 2002-12-24 | Chisso Corp | アミノ化担体、およびそれを用いた細胞性フィブロネクチン−ヘパリン複合体の吸着方法 |
| DE10258944A1 (de) * | 2002-12-17 | 2004-07-01 | B. Braun Medizintechnologie Gmbh | Vorrichtung zur Entfernung von bakteriellen Lipopolysacchariden oder/und Lipoteichonsäuren aus proteinhaltigen Flüssigkeiten sowie deren Verwendung zur Behandlung von Sepsis |
| US6861473B2 (en) * | 2003-02-28 | 2005-03-01 | Baxter International Inc. | Macromolecular ketoaldehydes |
| US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
| CN101903296B (zh) * | 2008-02-12 | 2013-08-14 | 3M创新有限公司 | 复合聚合物过滤介质 |
| JP2011133396A (ja) * | 2009-12-25 | 2011-07-07 | Sysmex Corp | 活性化部分トロンボプラスチン時間測定試薬、活性化部分トロンボプラスチン時間測定方法、及び血液凝固抑制物質の有無の判定方法 |
| US10231721B2 (en) | 2010-06-24 | 2019-03-19 | St. Croix Surgical Systems, Llc | Failsafe percutaneous wound barrier |
| EP4480582A1 (en) | 2013-01-18 | 2024-12-25 | Biomeme, Inc. | Analytic device |
| CN105765363B (zh) * | 2013-11-01 | 2020-05-08 | 生米公司 | 样品提取和制备装置 |
| EP3682024A4 (en) | 2017-09-15 | 2021-05-12 | Biomeme, Inc. | METHODS AND SYSTEMS FOR AUTOMATIC SAMPLE PROCESSING |
| JP7524061B2 (ja) | 2017-12-15 | 2024-07-29 | バイオミーム インコーポレイテッド | サンプルを分析するためのポータブル装置及び方法 |
| EP4213989A4 (en) | 2020-09-18 | 2025-01-15 | Biomeme, Inc. | Portable devices and methods for analyzing samples |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3099600A (en) * | 1961-01-26 | 1963-07-30 | Ormonoterapia Richter Spa | Chromatographic purification of heparin |
| US3337409A (en) * | 1963-11-20 | 1967-08-22 | Rexall Drug Chemical | Process for the recovery of heparin |
| JPS54112071A (en) * | 1978-02-22 | 1979-09-01 | Mitsui Petrochemical Ind | Method of filtering liquid |
| US4198314A (en) * | 1978-08-04 | 1980-04-15 | Warner-Lambert Company | Removal of heparin from heparin-containing blood plasma samples using a triethylaminoethyl cellulose tablet |
| US4199502A (en) * | 1978-08-04 | 1980-04-22 | Warner-Lambert Company | Removal of heparin from blood plasma samples using an insoluble protamine reaction product |
| DE2921924A1 (de) * | 1979-05-30 | 1980-12-04 | Biotest Serum Institut Gmbh | Geraet zur reversiblen und irreversiblen adsorption von blut und blutbestandteilen |
| US4226599A (en) * | 1979-06-20 | 1980-10-07 | Warner-Lambert Company | Removal of heparin from heparin-containing blood plasma samples using a triethylaminoethyl cellulose tablet |
| JPS5714640A (en) * | 1980-07-02 | 1982-01-25 | Toray Ind Inc | Separating membrane of methyl methacrylate type |
| US4473474A (en) * | 1980-10-27 | 1984-09-25 | Amf Inc. | Charge modified microporous membrane, process for charge modifying said membrane and process for filtration of fluid |
| US4523995A (en) * | 1981-10-19 | 1985-06-18 | Pall Corporation | Charge-modified microfiber filter sheets |
| US4702840A (en) * | 1982-02-05 | 1987-10-27 | Pall Corporation | Charge modified polyamide membrane |
| US4707266A (en) * | 1982-02-05 | 1987-11-17 | Pall Corporation | Polyamide membrane with controlled surface properties |
| GB2135207B (en) * | 1983-02-17 | 1986-02-05 | Shell Int Research | Process and apparatus for the removal of oil from an oil-in-water dispersion |
| DE3422494A1 (de) * | 1984-06-16 | 1985-12-19 | B. Braun Melsungen Ag, 3508 Melsungen | Verfahren und vorrichtung zur spezifischen adsorption von heparin |
| JPS62181056A (ja) * | 1985-10-07 | 1987-08-08 | アメリカン・ホスピタル・サプライ・コ−ポレイシヨン | ヘパリン被覆された濾過要素を有する血液濾過装置 |
| EP0267286B1 (en) * | 1986-03-28 | 1993-05-26 | ASAHI MEDICAL Co., Ltd. | Filter medium for selectively removing leucocytes |
| US4906374A (en) * | 1986-12-23 | 1990-03-06 | Pall Corporation | Filtration media with low protein adsorbability |
| CS261814B1 (en) * | 1987-03-04 | 1989-02-10 | Miroslav Prom Chem Csc Antal | Agent for heparine removing from blood in vitro |
| US5000854A (en) * | 1989-06-14 | 1991-03-19 | The University Of Michigan | Protamine-based filter device for removal of heparin from blood samples |
| US5133878A (en) * | 1989-11-17 | 1992-07-28 | Pall Corporation | Polymeric microfiber filter medium |
-
1990
- 1990-07-13 US US07/552,138 patent/US5151192A/en not_active Expired - Fee Related
-
1991
- 1991-07-09 AU AU80320/91A patent/AU653731B2/en not_active Ceased
- 1991-07-11 IL IL98799A patent/IL98799A0/xx unknown
- 1991-07-11 CA CA002046807A patent/CA2046807A1/en not_active Abandoned
- 1991-07-12 EP EP91111652A patent/EP0466178B1/en not_active Expired - Lifetime
- 1991-07-12 GB GB9115109A patent/GB2245844B/en not_active Expired - Fee Related
- 1991-07-12 DE DE69126643T patent/DE69126643T2/de not_active Expired - Fee Related
- 1991-07-13 KR KR1019910011955A patent/KR920002635A/ko not_active Withdrawn
- 1991-07-15 JP JP3174128A patent/JP2679894B2/ja not_active Expired - Lifetime
- 1991-08-17 TW TW080106537A patent/TW207958B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| DE69126643D1 (de) | 1997-07-31 |
| AU8032091A (en) | 1992-01-16 |
| TW207958B (enExample) | 1993-06-21 |
| IL98799A0 (en) | 1992-07-15 |
| JP2679894B2 (ja) | 1997-11-19 |
| EP0466178B1 (en) | 1997-06-25 |
| US5151192A (en) | 1992-09-29 |
| JPH04241873A (ja) | 1992-08-28 |
| AU653731B2 (en) | 1994-10-13 |
| EP0466178A1 (en) | 1992-01-15 |
| KR920002635A (ko) | 1992-02-28 |
| GB2245844A (en) | 1992-01-15 |
| GB2245844B (en) | 1994-10-26 |
| CA2046807A1 (en) | 1992-01-14 |
| GB9115109D0 (en) | 1991-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69126643T2 (de) | Methode und Vorrichtung zur Entfernung von Heparin | |
| DE69025287T2 (de) | Filtermedien mit niedriger Adsorptionsfähigkeit für Proteine | |
| DE60035219T2 (de) | Filter für die selektive entfernung von leukozyten | |
| DE69214466T2 (de) | Polymerbeschichtung | |
| DE69020248T2 (de) | Filtermaterial zum Abscheiden von Leukozyten und Verfahren zu seiner Herstellung. | |
| DE69016388T2 (de) | Filtermedium aus Polymermikrofaser. | |
| DE69603255T2 (de) | Verfahren zur modifizierung von oberflächen | |
| DE69012912T2 (de) | Membran mit einer hydrophilen Oberfläche. | |
| DE3782394T2 (de) | Immobilisiertes, physiologisch aktives material. | |
| DE2827109C2 (de) | Verfahren und Vorrichtung zur Abtrennung von organischen Verbindungen von Plasmaproteinen des Blutes | |
| EP1590065B2 (de) | Filter zur abtrennung von leukozyten aus vollblut/oder blutpräparaten, verfahren zur herstellung dieser filter, vorrichtung und verwendung | |
| DE69534647T2 (de) | Behälter und träger für die blutuntersuchung enthaltend einen blutkomponenten adhäsions-inhibitor | |
| EP0172437B1 (de) | Dialysemembran aus modifizierter Cellulose mit verbesserter Biokompatibilität | |
| DE69124206T2 (de) | Hochwirksame Abtrennung von lipoproteinischem Cholesterol niedriger Dichte aus Vollblut | |
| DE3412616C2 (enExample) | ||
| DE2812174C2 (de) | Die Blutgerinnung nicht fördernde, biologisch verträgliche Gegenstände | |
| DE69827229T2 (de) | Verwendung eines neutralen oder kationischen Polymers, das zur Verhinderung der Aktivierung der Blut-oder Plasmakontaktphase in Berührung mit einer teildurchlässigen Membran | |
| DE2326863A1 (de) | Verfahren zur herstellung biokompatibler und biofunktioneller materialien | |
| DE2431920B2 (de) | Mit copolymeren ueberzogenes adsorbensmaterial | |
| DE2735179B2 (de) | Hämoperfusionsadsorbens aus einem absorbierend wirkenden Material | |
| DE69530761T2 (de) | Methode und poröser träger zur entfernung von verunreinigungen | |
| DE2534317A1 (de) | Antikoerper, antigene bzw. antisera einschliessende fasern, verfahren zu deren herstellung und zur anwendung derselben | |
| DE3855127T2 (de) | Methode zur Entfernung von Granulozyten aus dem Blut und Gerät dafür | |
| DE69734862T2 (de) | Apparat zur Behandlung des Blutes durch extrakorporalen Blutkreislauf, sowie Verfahren zu seiner Herstellung | |
| DE69224517T2 (de) | Trägermaterial und biokompatibler Anionenanstauscher |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |